Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Indian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...

Brokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...

Specialty chemicals maker Anupam Rasayan India is set to acquire up to 43.3% of Bliss GVS Pharma for an estimated Rs 1,369.51 crore, with a...

Zydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...

Carlyle Group is building a global healthcare revenue cycle management platform. The firm acquired majority stakes in US companies Knack an...

Global investment firm Carlyle has acquired a majority stake in US healthcare revenue cycle management providers Knack RCM and EqualizeRCM....

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

Promoters are showing increased confidence in several Nifty 500 companies. Their shareholding has risen in the March 2026 quarter compared ...

EQT expects India to remain a top capital destination in its new Asia fund, with roughly one-third allocation historically. The firm sees s...

Glenmark Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray...

We expect to file 20-25 abbreviated new drug applications each year over the next 5 years and launch 10-20 products annually," Glenmark MD ...

The New Jersey-based specialty pharmaceutical firm Navakar has expertise in commercialising pharma products in the US as well as global mar...

The company plans to build a global manufacturing footprint, increase presence in complex generics, launching of specialty business in the ...

A day after announcing its biggest acquisition deal of $880 million, Lupin today said it will buy Germany-based Temmler Pharma's specialty ...